BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 22617227)

  • 1. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
    Wilke RA; Ramsey LB; Johnson SG; Maxwell WD; McLeod HL; Voora D; Krauss RM; Roden DM; Feng Q; Cooper-Dehoff RM; Gong L; Klein TE; Wadelius M; Niemi M;
    Clin Pharmacol Ther; 2012 Jul; 92(1):112-7. PubMed ID: 22617227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
    Ramsey LB; Johnson SG; Caudle KE; Haidar CE; Voora D; Wilke RA; Maxwell WD; McLeod HL; Krauss RM; Roden DM; Feng Q; Cooper-DeHoff RM; Gong L; Klein TE; Wadelius M; Niemi M
    Clin Pharmacol Ther; 2014 Oct; 96(4):423-8. PubMed ID: 24918167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
    ; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
    N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
    Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
    Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
    Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
    Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLCO1B1 variants and statin-induced myopathy.
    Vladutiu GD; Isackson PJ
    N Engl J Med; 2009 Jan; 360(3):304. PubMed ID: 19144951
    [No Abstract]   [Full Text] [Related]  

  • 7. The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
    Voora D; Shah SH; Spasojevic I; Ali S; Reed CR; Salisbury BA; Ginsburg GS
    J Am Coll Cardiol; 2009 Oct; 54(17):1609-16. PubMed ID: 19833260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
    Canestaro WJ; Austin MA; Thummel KE
    Genet Med; 2014 Nov; 16(11):810-9. PubMed ID: 24810685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care.
    Vassy JL; Brunette CA; Majahalme N; Advani S; MacMullen L; Hau C; Zimolzak AJ; Miller SJ
    Contemp Clin Trials; 2018 Dec; 75():40-50. PubMed ID: 30367991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
    Hou Q; Li S; Li L; Li Y; Sun X; Tian H
    Medicine (Baltimore); 2015 Sep; 94(37):e1268. PubMed ID: 26376374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics and adverse drug reactions: the case of statins.
    Giorgi MA; Caroli C; Arazi HC; Di Girolamo G
    Expert Opin Pharmacother; 2011 Jul; 12(10):1499-509. PubMed ID: 21568825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink.
    Carr DF; O'Meara H; Jorgensen AL; Campbell J; Hobbs M; McCann G; van Staa T; Pirmohamed M
    Clin Pharmacol Ther; 2013 Dec; 94(6):695-701. PubMed ID: 23942138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics and drug toxicity.
    Nakamura Y
    N Engl J Med; 2008 Aug; 359(8):856-8. PubMed ID: 18650508
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pharmacogenetic analysis can predict adverse effects of statins].
    Garwicz D; Wadelius M
    Lakartidningen; 2013 May 7-21; 110(19-20):951-2. PubMed ID: 23745502
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients.
    Toms TE; Smith JP; Panoulas VF; Douglas KM; Saratzis AN; Kitas GD
    Musculoskeletal Care; 2010 Mar; 8(1):2-9. PubMed ID: 19642078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial.
    Vassy JL; Gaziano JM; Green RC; Ferguson RE; Advani S; Miller SJ; Chun S; Hage AK; Seo SJ; Majahalme N; MacMullen L; Zimolzak AJ; Brunette CA
    JAMA Netw Open; 2020 Dec; 3(12):e2027092. PubMed ID: 33270123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
    Cooper-DeHoff RM; Niemi M; Ramsey LB; Luzum JA; Tarkiainen EK; Straka RJ; Gong L; Tuteja S; Wilke RA; Wadelius M; Larson EA; Roden DM; Klein TE; Yee SW; Krauss RM; Turner RM; Palaniappan L; Gaedigk A; Giacomini KM; Caudle KE; Voora D
    Clin Pharmacol Ther; 2022 May; 111(5):1007-1021. PubMed ID: 35152405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group.
    Santos PC; Soares RA; Nascimento RM; Machado-Coelho GL; Mill JG; Krieger JE; Pereira AC
    BMC Med Genet; 2011 Oct; 12():136. PubMed ID: 21992719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms.
    Linskey DW; English JD; Perry DA; Ochs-Balcom HM; Ma C; Isackson PJ; Vladutiu GD; Luzum JA
    Pharmacogenet Genomics; 2020 Dec; 30(9):208-211. PubMed ID: 32453264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach.
    Tsamandouras N; Dickinson G; Guo Y; Hall S; Rostami-Hodjegan A; Galetin A; Aarons L
    Pharm Res; 2015 Jun; 32(6):1864-83. PubMed ID: 25446771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.